ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System) ...
The US Food and Drug Administration (FDA) has expanded the indication for the more rapid-acting version of insulin aspart (Fiasp, Novo Nordisk) for use in insulin pumps. Injectable and intravenous ...
Fiasp (insulin aspart) is a brand-name medication prescribed to help manage blood sugar levels in adults and children with diabetes. As with other drugs, Fiasp can cause side effects, such as low ...
A novel investigational fully automated "artificial pancreas" system that combines rapid-acting insulin aspart (Fiasp, Novo Nordisk) and pramlintide (Symlin, AstraZeneca) performed similarly to a ...
The approval was based on data from an active-controlled, treat-to-target trial (Onset7) that included 777 pediatric patients (aged 2 to 17 years) with type 1 diabetes. The Food and Drug ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. This medicine is new or being used ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. This medicine is new or being used ...
The FDA approved Novo Nordisk’s Fiasp, an insulin aspart injection to be used as a mealtime insulin option for children with diabetes, the company announced Jan. 6. Fiasp is the first and only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results